Purpose: to assess the safety and efficacy of infliximab in the treatment of uveitis associated with Behcet's disease. Methods: fifty patients with Behcet's related uveitis were included in this prospective comparative study. Cases were divided into 2 groups; group A(25 patients) received infliximab and group B (25 patients) received oral steroids. All cases were followed up to one year. Results: In group A, the mean BCVA (logMAR) improved from 0.48±0.14 at baseline to 0.07±0.12 three months after treatment. Also, the number of cases with grade 0 AC cells increased from 0 before starting treatment to 18 after 3 months. In group B, the mean BCVA (logMAR) improved from 0.47±0.13 at baseline to 0.17±0.15 three months after treatment. Also, the number of cases with grade 0 AC cells increased from 0 before starting treatment to 14 after 3 months. Conclusion: Infliximab is both safe and effective in treating uveitis associated with Behcet's disease. Studies with larger sample size and longer follow-up periods are needed to confirm the results.
Abozaid, M., & Saad-eldin, R. (2023). The Use of infliximab in Treatment of Uveitis Associated with Behcet's disease. International Journal of Health Sciences (Egypt), 1(2), 46-51. doi: 10.21608/ijhegy.2023.202225.1013
MLA
Mortada Abozaid; Rana Nasser Saad-eldin. "The Use of infliximab in Treatment of Uveitis Associated with Behcet's disease", International Journal of Health Sciences (Egypt), 1, 2, 2023, 46-51. doi: 10.21608/ijhegy.2023.202225.1013
HARVARD
Abozaid, M., Saad-eldin, R. (2023). 'The Use of infliximab in Treatment of Uveitis Associated with Behcet's disease', International Journal of Health Sciences (Egypt), 1(2), pp. 46-51. doi: 10.21608/ijhegy.2023.202225.1013
VANCOUVER
Abozaid, M., Saad-eldin, R. The Use of infliximab in Treatment of Uveitis Associated with Behcet's disease. International Journal of Health Sciences (Egypt), 2023; 1(2): 46-51. doi: 10.21608/ijhegy.2023.202225.1013
', './data/ijhegy/coversheet/421687795180.jpg'))
View on SCiNiTO